2023 ANNUAL REPORT



The Australian Breast Device Registry is supported by funding from the Australian Government, Department of Health and Aged Care, under the National Clinical Quality Registry Program.

During 2023...



12,645 PROCEDURES CAPTURED*

10,566 patients recruited20,380 new devices captured

< 1% opt-out rate

*At operation-level



443 CONTRIBUTING CLINICIANS

281 plastic surgeons

136 breast/general surgeons

26 cosmetic clinicians



239 CONTRIBUTING HEALTH SERVICES

73.6% private hospitals, clinical and day surgeries26.4% public hospitals

Across all States/jurisdictions except WA public hospitals

From 2012 - 2023



192,706

DEVICES

Since 2012, the ABDR has recorded **211,493 procedures** (at breast-level) and recruited **98,460 patients.**

THE ABDR CAPTURED **86.4% OF DEVICES** SOLD IN 2023
AND ~72% OF PROCEDURES
PERFORMED (2022-23 DATA)

According to data provided by the Therapeutic Goods Administration and publicly available data from the Australian Institute of Health and Welfare

Devices inserted overseas

During 2012-2023, there were 5,492 procedures performed involving the removal of devices that had originally been inserted overseas.

THE AVERAGE RATE OF REVISION AT 12 MONTHS FOR INSERTIONS MADE BETWEEN 2020 AND 2022

3.4% FOR RECONSTRUCTIVE CASES **0.7%** FOR COSMETIC CASES

new cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) were recorded taking the total number of cases recorded by the ABDR to 67 since 2015.

7 - 10 YEARS

THE MOST COMMON DURATION BETWEEN IMPLANT INSERTION AND DATE OF REVISION (BIA-ALCL CASES)

SEROMA/HAEMATOMA

THE MOST COMMON CLINICAL ISSUE ASSOCIATED WITH BIA-ALCI



abdr.org.au



abdr@monash.edu



@BreastDeviceReg





2023 ANNUAL REPORT



3,386 (11.6%)

RECONSTRUCTIVE PROCEDURES IN 2023



~75% OF INITIAL RECONSTRUCTION PROCEDURES WERE INSERTIONS EXPLANT ONLY
(REMOVAL)
RECONSTRUCTIVE
PROCEDURES
INCREASED FROM
0.8% IN 2016 TO 5.5%
IN 2023

76.4% OF RECONSTRUCTION
PROCEDURES WERE
PERFORMED POST
MASTECTOMY FOR CANCER
TREATMENT

Direct to implant (one stage) procedures increased from 47.5% in 2016 to 66.9% in 2023



For two-stage procedures, ~75% of exchanges occurred within 9 months and 86.1% within 12 months (2012-23)

50.2
YEARS OLD AT TIME OF PROCEDURE (MEDIAN AGE)

SMOOTH

The most common (65.9%) shell type for implants inserted in 2023 for reconstructive purposes.



The most common (69.5%) shape for implants inserted in 2023 for reconstructive purposes.

Capsular contracture

was the most common (35.1%) complication (out of all patients with a reported complication) identified at revision for reconstructive procedures



INSERTION-ONLY COSMETIC PROCEDURES



REVISIONS (COSMETIC PROCEDURES)



EXPLANT-ONLY
COSMETIC
PROCEDURES

Capsular contracture

was the most common (1.6%) cause for 8-year post-primary implant insertion for cosmetic procedures

Revisions due to complications 8-years post insertion for cosmetic procedures

was 3.7% for polyurethane, 3.4% for textured and 3.2% for smooth implants

7,835

NEW COSMETIC PROCEDURES RECORDED IN 2023 - THE LOWEST NUMBER RECORDED IN THE REGISTRY SINCE 2016



abdr.org.au



abdr@monash.edu



@BreastDeviceReg



